It’s developing products for glaucoma and other conditions.
NEW YORK — Biopharmaceutical company Eyenovia Inc. has closed on an initial public offering of 2.73 million shares of common stock.
Eyenovia received $27.3 million in gross proceeds from the offering, according to a press release. The company's common shares are traded on the Nasdaq Capital Market under the ticker symbol "EYEN."
Eyenovia is "a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye," according to the release.
Eyenovia’s pipeline is focused on micro-therapeutics for glaucoma and other eye diseases. The company's website says its technology "will replace outdated dropper technology for improved patient experience and compliance."